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1. Summary 
Pneumococcal infections cause a large global health burden and the search 
for serotype independent vaccines continues. Existing conjugate vaccines 
reduce nasopharyngeal colonisation with target serotypes. Such mucosal 
effects of novel antigens may be likewise important. CD4+ Th17 cell 
dependent antibody-independent reductions in colonisation and enhanced 
clearance has been described in mice. We here describe methods to 
evaluate Th17 cytokine responses to potential pneumococcal vaccine 
candidate antigens in a human cell culture system, using adenoidal and 
peripheral blood Ficoll-density gradient separated mononuclear cells. 
Optimal detection of IL-17A was at day 7 and of IL-22 at day 11 in these 
primary cell cultures, and MACS removal of CD45RO+ cells abolished these 
responses. Age-associated increases in magnitude of responses were only 
evident for IL-17A in adenoidal cells. There was strong evidence of 
correlation between individual IL-17A and IL-22 responses after 
pneumococcal antigen stimulation (p<0.015). Intra-cellular cytokine staining 
following PMA/Ionomycin stimulation demonstrated that >30% CD4 T cells 
positive for IL-22 express the innate markers γδT-cell receptor and/or CD56 
with much lower proportions for IL-17A+ cells (p<0.001). Natural acquired 
responses to several vaccine candidate antigens were observed and notable 
for consistent absence, particularly in blood, to PhtD (p<0.0001), recently 
shown to lack impact on colonisation in a clinical trial of a PhtD-containing 
conjugate vaccine in infants. This approach has the potential to assist 
vaccine antigen design aimed at reducing pneumococcal carriage and 
transmission. 
 
 
2. Introduction 
Streptococcus pneumoniae (pneumococcus) remains a global challenge and 
cause of much disease including pneumonia, meningitis, sepsis and otitis media 
and is a particular challenge in developing countries. Pneumococcus accounts 
for 11% of all deaths in children under 5 years of age resulting in up to a million 
childhood deaths every year (1, 2). Of growing global concern are the 
emergence of non-vaccine serotypes and antibiotic resistant strains of 
pneumococcus (3, 4). 
 
Pneumococcus is a commensal of the human upper respiratory tract and there 
are more than 90 serotypes. Colonisation of the nasopharynx with 
pneumococcus is common in young children and decreases with age (5-7), it is 
not usually associated with significant illness whereas development of invasive 
pneumococcal disease is, relatively speaking, rare. Transmission between 
children and to other family members sustains the bacteria within a community 
(8). The introduction of multivalent pneumococcal conjugate vaccines (PCV) 
has resulted in overall decreases in the incidence of pneumococcal disease, but 
overall colonisation rates in children have changed little as non-vaccine 
serotypes replace formerly dominant vaccine types and also now cause some 
disease undermining vaccine (9-11). 
 
Thus, development of serotype-independent pneumococcal vaccines is a 
priority in the fight against pneumococcus. If, like PCVs, such vaccines are to 
impact on disease by reducing carriage and transmission, understanding 
naturally-acquired mucosal immune responses to pneumococcus and how they 
may affect pneumococcal colonisation could guide antigen selection and 
vaccine formulation. Antibody-independent CD4+ T cell dependent prevention 
of pneumococcal colonisation has been demonstrated in mice (12-14). A role 
for CD4+ Th17 cells which that can kill and clear pneumococci by recruiting 
neutrophils to the site of infection, has been proposed (15). Th17 cells exist in 
adults and children(15), and produce both Interleukin-17A (IL-17A) and 
Interleukin -22 (IL-22) (16, 17). The stimulation of production of IL-17A and IL-
22 by candidate pneumococcal vaccine antigens could indicate their capacity to 
influence pneumococcal colonisation either by preventing acquisition or 
promoting clearance.  
 
Here we describe optimisation of measurement and characteristics of Th17 
responses in human primary cell cultures from blood and adenoidal tissue 
(nasal associated lymphoid tissue) of children, and preliminary use of this 
technique to screen potential pneumococcal vaccine candidate antigens. We 
show that, the case of one antigen, consistent lack of demonstrable responses 
is associated with recently reported lack of efficacy in human trials against 
carriage.  
 
3. Materials and methods 
 
3.1 Subjects and samples 
With informed consent, adenoids were collected from children aged 1-14 years 
(eligibility age range 0-15yrs), who were undergoing routine adenoidectomy or 
adenotonsillectomies at the Bristol Royal Hospital for Children. Up to 10ml of 
peripheral blood from each child were collected using 1% heparin (Sigma-Aldrich 
Company Ltd., UK) as the anti-coagulant in some cases. Children were healthy at 
the time of surgery and were excluded if they had any known immunodeficiency 
or if they had received treatment likely to cause immunosuppression within 2 
weeks of surgery.  Ethical approval was obtained from the North Somerset & 
South Bristol Research Ethics Committee and in some cases also from the 
research committee of PATH, one of the funders of this work. 
 
3.2 Antigens   
The whole-cell killed unencapsulated pneumococcal antigen (WCA) was made 
as described in (18) following “Good manufacturing Practice” (GMP) (19) at a 
concentration of 1x106cfu/ml as determined in previous experiments (data not 
shown). 
Recombinant proteins Choline binding protein A (CbpA), Pneumococcal surface 
adhesin A (PsaA) and Pneumococcal surface protein A (PspA) were purified 
from recombinant E.coli expressing the respective cloned genes (20, 21). 
Recombinant protein Pneumococcal histidine triad protein D (PhtD) was 
produced as previously described (22). All proteins were used at a 
concentration of 8µg/ml to stimulate optimal CD4+ T cell proliferation as 
determined in previous experiments (data not shown). 
 
3.3 Cell isolation and culture 
Adenoidal tissue was processed within 24h of collection and collected into 
Hanks' Balanced Salt Solution (HBSS)/ 2% Hepes (Thermo Scientific/Life 
Technologies, USA and Sigma-Aldrich Company Ltd., UK) with 10% 
Penicillin/Streptomycin (Sigma-Aldrich Company Ltd., UK). Peripheral blood 
was processed within 6h of collection and was prepared by diluting it 50:50 with 
HBSS/2% Hepes. Mononuclear cells from adenoids and peripheral blood were 
separated on Ficoll-density gradients as previously described (23). Cells were 
cultured in 48-well culture plates at 1x106 cells/ml in a 1ml volume, in either 
complete RPMI media with 10% Foetal bovine serum (Sigma-Aldrich Company 
Ltd., UK) for cytokine analysis, or in complete RPMI media/2% human serum 
(Sigma-Aldrich Company Ltd., UK) for intra-cellular cytokine analysis.   
 
3.4 Cell depletions 
Comment [TJM1]: Methods are 
correct as far as I am concerned 
Memory T cells (CD45RO+) were depleted from the mononuclear cell 
population using positive selection magnetic-activated cell sorting (MACS) 
according to the manufacturer’s guidelines (Miltenyi Biotech, Germany). A 
positive control (“add back”) was made by mixing the depleted cells with the 
positively selected cells retained on the magnet during the cell separation 
procedure. The purity of these cell suspensions (CD45RO- and CD45RO+) was 
confirmed by immunofluorescence staining (CD4-APC, CD45RO-FITC and 
CD45RA-PE-Cy7 (BD Biosciences, UK)) and flow cytometry (FACS Canto II 
(BD Biosciences, UK; analysis with FlowJo (FlowJo, LLC, USA) and then re-
mixed at a 1:1 ratio.  
 
3.5 IL-17A and IL-22 immunoassays 
Cells were stimulated with or without antigen, and IL-17A was measured in the 
cell supernatant collected on day 7 using a Human IL-17A ELISA Ready-Set-Go 
kit according to the manufacturer’s instructions (Affymetrix eBiosceinces,USA).  
IL-22 was measured from cell supernatants mostly collected at day 11 using a 
Human IL-22 ELISA Ready-Set-Go kit according to the manufacturer’s 
instructions (Affymetrix eBiosciences,USA). In most cases the same cell 
supernatants were used for both cytokine assays. Supernatants were stored at -
20oC for short term and at -80oC for long term storage. 
  
3.6 Intra-cellular cytokine production 
Intra-cellular cytokine staining was conducted on day 7 after cell stimulation with 
or without antigen. Cells were re-stimulated with antigen late on day 6 to boost 
their cell specific cytokine responses. On day 7 PMA 0.05µg/ml, Ionomycin 
1µg/ml (Sigma-Aldrich Company Ltd., UK) and Golgistop (BD Biosciences, UK) 
were added for 5 hours. Cell viability staining, cell surface staining and the 
intracellular cytokine staining processes were carried out using a BD 
Cytofix/Cytoperm Fixation/Permeabilization Kit according to the manufacturer’s 
instructions (BD Biosciences, UK). Fixable viability dye eFluor780 was 
(Affymetrix eBiosceinces,USA) was used to assess cell viability. Cell surface 
antibody markers CD4 Alexa Fluor700 (BD Biosciences, UK), CD56 PE-Cy7/ 
Brilliant Violet 510 (BD Biosciences, UK/ Biolegend, USA), TCR yδ FITC/ PE-
Cy5.5 (BD Biosciences, UK/ Beckman Coulter, USA) and intracellular 
antibodies IL-17A PE/ Brilliant Violet 605 (Affymetrix eBiosceinces,USA/ 
Biolegend, USA) and IL-22 eFluor660 (Affymetrix eBiosceinces,USA) were 
used. The fixed and stained cells were left overnight at 4oC to reduce 
autofluorescence before being analysed on a LSR II flow cytometer (BD 
Biosciences, UK), where 20,000 live cells in the lymphocyte gate were collected 
per stimulation. Analysis was carried out using the software program FlowJo, 
and only live cells in the lymphocyte gate were analysed. 
 
3.7 Statistical analysis 
 
Significance of differences between groups was analysed using paired student 
t-tests. The relationship between age and cytokines responses were was 
compared using linear regression analysis. Pearson correlation was used to 
investigate correlations between individual cytokines responses. Group mean 
cytokine responses to the panel of antigens were compared by repeated 
measures one-way ANOVA. Statistical analysis was performed using GraphPad 
Prism version 6 (GraphPad Software, USA). 
 
4. Results 
 
Identifying the optimal time detection point for Th17 cytokines IL-17A and 
IL-22 in response to WCA 
In time course experiments using PBMC and in AMNC stimulated with WCA, 
Th17 cytokine IL-17A (Fig. 1a) and IL-22 (Fig. 1b) responses, when present, 
were maximal at days 7 and 11 respectively and these timings were used in 
subsequent experiments. 
 
Memory T cells are essential for IL-17A production in blood 
In two experiments using PBMC, depletion of memory T cells (CD45RO+) 
almost entirely eliminated detectable IL-17A responses (Fig 2.a), which were 
restored by their replacement (Fig 2.b). This finding was reconfirmed in four 
additional children whose un-depleted PBMC IL-17A responses were median 
(range) 40.5 (6.3-65.6) pg/ml on day 5, and CD45RO-depleted (99.83% purity)  
IL-17A responses 0 (0-0.4) pg/ml (data not shown). 
 Relationships between cytokine responses and age 
Apart from IL-17A responses in adenoidal cells for which an association was 
apparent, there was little evidence that age predicted the size of IL-17A and IL-
22 responses to WCA in the children studied (Fig 3).  
 
Correlation between IL-17A and IL-22 responses 
There was strong positive correlation in the size of PBMC and AMNC IL-17A 
and IL-22 responses in individual subjects both to WCA and to CbpA stimulation 
(Fig 4).   
 
Intracellular cytokine detection of IL-17A and IL-22 in response to antigen 
stimulation 
For intracellular cytokine staining work, IL-22 signals were sought after 7 days 
rather than the optimal day 11 (Fig 5) as there were limited available cells. Live 
lymphocyte gating (based on forward and side scatter parameters) in flow 
cytometric staining for intracellular IL-17A and IL-22 showed strong evidence for 
increases of 2% or more above the background following stimulation with the 
recombinant pneumococcal antigen CbpA (Fig 5.a). 
50% or more IL-17A+ live lymphocytes expressed the cell surface marker 
CD4+, with a somewhat lower percentage of IL-22+ AMNC expressing CD4 (Fig 
5. b). Following stimulation with the antigen WCA there was very strong 
evidence of an increase in the proportion of IL-17A+ AMNC expressing CD4 
compared to cultured cells that were stimulated with only PMA/Ionomycin. 
 
Expression of innate surface markers by CD4+ AMNC expressing IL-17A 
and IL-22. 
There was very strong evidence that a much higher proportion of IL-22+ CD4+ 
AMNC expressed one, the other or both of the innate cellular markers CD56 
and TCR-γδ, than IL-17A+ CD4+ AMNC both before and after antigen 
stimulation (Fig 6). 
 
IL-17A and IL-22 responses to a panel of pneumococcal antigens 
Cytokine release by peripheral blood and AMNC following stimulation with 
pneumococcal antigens including 3 additional proteins previously investigated 
as candidate vaccines were measured. Results showed significant variation 
between antigens (Fig 7), and in particular there was little apparent response to 
the surface protein PhtD in PBMC, while responses to the additional proteins 
PsaA and PspA were weak in AMNC. 
 
5. Discussion 
We defined IL-17A and IL-22 responses to pneumococcal antigens in adenoidal 
and peripheral blood mononuclear cells aiming to develop tools with which to 
evaluate Th17 cell immune responses to candidate pneumococcal vaccine 
antigens. This may permit elucidation of their effects on colonisation and thus 
preventing transmission. 
 
Previous Th17 experiments in mice found day 3 to be optimal to detect IL-17A 
responses, and IL-17A can also be detected from human pharyngeal tonsil 
mononuclear cells after 3 days (15). However, we have previously shown that 
CD4+ cell proliferation in response to pneumococcal antigens in children are 
optimal after 7 days of stimulation in culture (24) and likewise in the 
experiments presented here, 7 days of culture were optimal for IL-17A detection 
while 11 days was the best time for IL-22 detection (figure 1). We have 
previously demonstrated clearer and more reliable mucosal responses in 
adenoidal than tonsillar cells (25). Although these relatively slow response rises 
might suggest that these are not memory responses following previous 
exposure, depletion of CD45RO cells resulted in their almost complete 
disappearance (figure 2), confirming that they are anamnestic albeit not 
extremely rapid in concordance with previous studies of other aspects of these 
mucosal cellular immune responses (24). 
 
Both rates of colonisation and of invasive disease due to pneumococcus drop 
rapidly with increasing age in young children (5-7), suggesting progressive rises 
in specific mucosal immunity either in response to exposure, or through immune 
maturation or both. Both we (5) and others have shown evidence of emergence 
of specific B cell immunity to pneumococcal antigens particularly during the 
second year of life (7, 26). IL-17A responses to pneumococcal antigens in blood 
leukocytes are higher in adults than children and vary between children in 
different populations, possibly due to different levels of exposure (15, 27). In the 
results presented here, upward trends in Th17 responses with age were not 
convincingly demonstrated in blood although there was evidence of rises in 
adenoidal cellular elaboration of IL-17A in response to pneumococcal 
stimulation (figure 3). It is possible that clearer age-dependency was not seen in 
this study owing to other potentially confounding factors including variable 
recencytiming of recent  of exposure and colonisation. Alternatively, or in 
addition, much of any cytokine increase may occur by the end of the second 
year of life as seen for antibodies to pneumococcal antigens (5) while the 
children studied here we nearly all aged 2 years or older. 
 
The classic Th17 pathway shows production of IL-17A and IL-22 to be from 
CD4+ T cells under the influence of TGF-β, IL-6 and IL-23 (15, 28-30). Given 
existing evidence that mucosal immunity to colonisation by pneumococcus can 
be antibody independent and CD4+ T cell dependent in mice (14, 15), and that  
CD4+ T cells may be important in protection of humans against pneumococcal 
colonisation and disease, as for example in HIV-infected individuals with 
reduced numbers of CD4+ T cells and high risk of this infection (31), the 
question arises whether CD4+ T cells are an important cellular source of IL-17A 
and IL-22. While it was clear that both cytokines were elaborated by cells falling 
within the lymphocyte scatter gate, our results suggest that CD4+ T cells are a 
source of IL-17A following stimulation with pneumococcal antigens, this was not 
clearly demonstrated for IL-22 under the conditions we used (figure 5). 
Nevertheless, we did show evidence of strong correlation at an individual level 
between the size of IL-17A and IL-22 responses measured after pneumococcal 
antigen stimulation both in AMNC and PBMC (figure 4). Further characterisation 
of CD4+ T cells expressing the two cytokines both before and after 
pneumococcal antigen stimulation showed that those producing IL-22 were 
much more likely to be expressing innate cell phenotypes (figure 6).  Both 
innate NK T cells (32, 33) and TCR- Ƴδ cells (34, 35) have previously been 
shown to be sources of IL-17A and IL-22, and both these cell types have been 
shown to recruit neutrophils to the pneumococcal infection site (36, 37). Our 
observations extend these observations to include CD4+ T cells expressing 
innate markers as a potential source of IL-22, particularly in the human upper 
respiratory tract. 
 
We and others have previously investigated mucosal and systemic B cell and T 
cell CD4+ responses to several pneumococcal antigens including WCA, CbpA, 
PsaA and PspA (5, 12, 23, 24, 38). These antigens have also been shown to 
have protective effects in murine models of pneumococcal colonisation and 
infection (39-41). There is recent interest in PhtD as a vaccine candidate 
antigen (22). The IL-17A and IL-22 responses we demonstrate here to these 
antigens in primary human cell cultures, notwithstanding wide inter-individual 
variation, demonstrate significance differences between antigens as well (figure 
7). The relatively larger responses seen in blood than adenoidal cells occur in 
the context of much lower background cytokine production by un-stimulated 
cultures and a known lower T-regulatory environment (42). Of particular note 
are were the relative lack of responses to PhtD, an antigen which has recently 
been shown to lack efficacy against pneumococcal colonisation in children (43). 
Although it has been proposed that this and related pneumococcal proteins, 
which are released extra-cellularly by the bacterium in large quantities, might 
act as a sink for potentially opsonophagocytosing antibodies (44), our data 
suggest PhtD may also fail to induce mucosal cellular immune responses. , in 
addition.   
 
We here describe Th17 responses to pneumococcal antigens in human cell 
cultures in detail. This approach not only allows detailed description of the 
immunological responses to pneumococcus in the upper respiratory tract of 
young children, but also has potential to guide antigen design and selection for 
candidate vaccines aiming to impact upon carriage and transmission. Future 
studies should seek to elucidate whether such responses reliably predict 
protection against acquisition or clearance of carriage in children having 
repeated evaluation of colonisation over time. 
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Figure 1.  Detection of Th17 cytokines (a) IL-17A and (b) IL-22 in three 
children’s PBMC, and in one child’s AMNC after WCA stimulation over a 15 day 
time course. Each data point represents a child’s cytokine response and the 
background has been subtracted. Each supernatant was taken from a different 
well of cells at each time point. 
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Figure 2.  The effect of depleting memory T cells (CD45RO) from PBMC had 
on IL-17A responses to WCA.  Each data point represents a child’s IL-17A 
response to WCA over a 9 day time course in (a) undepleted PBMC and in 
memory T cell depleted PBMC, and in (b) the add back PBMC population of 
memory T cells and naïve T cells (CD45RA). The purity of the CD45RO 
depleted population in child one was 99.93%, and in child two it was 99.78% 
(data not shown). Due to a limitation with the number of cells available for child 
1 the add back experiment could only be conducted between days 5-9. At each 
time point the background has been subtracted, and the supernatant was taken 
from a different well of cells. 
 
 
 Figure 3. The association between age and IL-17A and IL-22 responses (above 
background) to WCA in (a) PBMC and (b) AMNC. Each data point represents a 
child’s IL-17A or IL-22 response at day 7 or 11 respectively to WCA. n = 37-39. 
Linear regression lines are shown with the r2 values. 
 
 
 
 
 
  
Figure 4.  Correlation in children of their IL-17A and IL-22 responses in (a) 
PBMC and in (b) AMNC to WCA and to CbpA. Each data point represents a 
child’s IL-17A and IL-22 response to WCA at day 7 or day 11 respectively, and 
the background has been subtracted. The n values range from 26-38. Pearson 
correlation was used to generate the correlation coefficient value, r, and a two-
tailed P value. 
 
 
 
 
 Figure 5. Intracellular cytokine staining analysis to identify IL-17A+ and IL-22+ 
expressing AMNC in response to WCA and CbpA at day 7, and to determine 
their CD4+ expression level. (a)  The percentage of live lymphocytes producing 
IL-17A or IL-22.  The average percentage of live cells in the lymphocyte gate 
was 59.5%, n=14 (data not shown). (b) Comparison of the percentage of 
cytokine producing live lymphocytes expressing CD4+ in response to WCA and 
CbpA. Statistical analysis was conducted using a paired t-test with the p values 
shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6. Expression of innate cellular markers on CD4+ IL-17A+ and IL-22+ 
AMNC. Each bar represents the mean percentage of live CD4+ cytokine 
producing cells expressing combinations of the cell surface markers CD56 and 
TCR-γδ in response to WCA and to CbpA.  n=14 and a paired t-test was used 
to compare the IL-17A+ cells expressing combinations of the innate cellular 
markers, with live IL-22+ cells expressing combinations of the innate cellular 
markers, the p values are shown. 
 
 Figure 7.  IL-17A and IL-22 responses to WCA and to a panel of pneumococcal 
antigens – CbpA, PsaA, PspA and PhtD - in (a) PBMC and (b) AMNC.  Each 
data point represents a child’s IL-17A or IL-22 response. The background is 
shown (media) for reference, however the background has been subtracted 
from the data points showing the responses to each of the stimulations.  PBMC 
n=16 and AMNC n=14. The bar represents the mean. Comparing group means 
(excluding the media background) was conducted by repeated measures one-
way ANOVA with the p values shown. 
